The association of hepatitis c virus infection status with serum glucose levels

• Published in: BMC gastroenterology Vol. 19; no. 1; p. 86
• Main Authors: Li, Yinping, Wang, Xiaomei, Yu, Ge, Sun, Haibo, Lv, Juan, Chi, Xiumei, Wu, Ruihong, Gao, Xiuzhu, Niu, Junqi
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 13.06.2019; BioMed Central; BMC
• Subjects: Adult; Antiviral Agents - administration & dosage; Antiviral treatment; Biological response modifiers; Blood glucose; Blood Glucose - analysis; Body mass index; Care and treatment; Chronic hepatitis C; Drug Therapy, Combination; Fasting; Fasting - blood; Fasting blood glucose; Female; Gastroenterology; Glucose; Glucose metabolism; Health aspects; Hepacivirus; Hepatitis C; Hepatitis C virus; Hepatitis C, Chronic - blood; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - virology; Humans; Infection; Insulin; Insulin - blood; Insulin Resistance; Interferon; Interferon alpha; Interferon-alpha - administration & dosage; Male; Medical research; Middle Aged; Patient outcomes; Peptides; Retrospective Studies; Ribavirin; Ribavirin - administration & dosage; Sustained Virologic Response; Sustained virological response; Virus diseases; α-Interferon; China; Sustained virological response; Chronic hepatitis C; Fasting blood glucose; Antiviral treatment
• ISSN: 1471-230X; 1471-230X
• DOI: 10.1186/s12876-019-1003-3

Hepatitis C virus (HCV) infection is commonly associated with a disturbance of glucose metabolism. However, there have been conflicting reports on whether the clearance of the HCV may be followed by changes of serum blood glucose and insulin resistance. The aim of the present study was to evaluate the impact of HCV and antiviral treatment on serum glucose levels and other glucose metabolism parameters. A retrospective analysis of 306 HCV-infected patients was performed. Fasting serum blood glucose (FBG) levels in these patients were compared with that of 325 healthy individuals. Serum parameters of glucose metabolism were measured in 183 patients with chronic hepatitis C at baseline, at the end of interferon α-2b plus ribavirin treatment, and at 24 weeks post-treatment. Patients with HCV infection had significantly higher FBG level than healthy controls (5.57 ± 0.74 vs. 5.11 ± 0.83 mmol/l, P < 0.001). After antiviral treatment, we found a significant reduction in FBG levels regardless of the outcome of treatment. However, after stopping treatment the serum FBG levels were significantly elevated in the sustained virological response (SVR) and non-responder groups, and maintained high level until week 24 post-treatment. In both groups, the levels of serum FBG after 24 weeks post-treatment were still lower than pre-treatment levels. In sustained responders, fasting insulin (P = 0.007), C-peptide (P < 0.001) and HOMA-IR (P < 0.001) significantly decreased, and the insulin sensitivity index (ISI) increased (P < 0.001) at the end of the treatment comparing with pre-treatment levels, while no significant difference was observed in non-responder group. HOMA-β values were increased in both groups at the end of treatment (both P < 0.001). The total serum FBG level in HCV infected patients was higher than that in healthy controls. Clearance of HCV was associated with reduced glucose and improved insulin resistance.